New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 10, 2013
10:17 EDTESRX, CTRXAnalyst says Express Scripts won't be hurt by private exchanges
Express Scripts (ESRX), which provides pharmacy benefit management services, is unlikely to be significantly hurt by private health insurance exchanges, research firm Jefferies believes. Investor worries about the impact of such exchanges on the company is overdone, the firm added. WHAT'S NEW: Following reports yesterday that several major companies are looking to place their retired workers into a private health insurance exchange, Jefferies analyst Brian Tanquilut wrote that such exchanges have been around for several years and have not significantly affected Express Scripts or its competitors. Moreover, many investors do not realize that Express Scripts' profit margins from the exchanges are not much lower than its margins from the large companies, Tanquilut contended. Finally, as a result of the shift of beneficiaries onto private exchanges, Express Scripts will have the opportunity to win new customers currently covered by its competitors, the analyst believes. He expects the stock to start advancing in the fourth quarter of this year and kept a Buy rating on the shares. WHAT'S NOTABLE: Express Scripts' stock fell slightly in an up market yesterday, as did shares of its competitor Catamaran (CTRX). TODAY'S PRICE ACTION: In early trading today, Express Scripts added 0.5% to $65 and Catamaran rose 0.45% to $45.60
News For ESRX;CTRX From The Last 14 Days
Check below for free stories on ESRX;CTRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
09:04 EDTESRXOn The Fly: Pre-market Movers
Subscribe for More Information
July 29, 2014
16:32 EDTESRXExpress Scripts sees FY15 retention rate 92%-93%
Subscribe for More Information
16:30 EDTESRXExpress Scripts reports Q2 adjusted claims 324.5M
Subscribe for More Information
16:30 EDTESRXExpress Scripts sees Q3 adjusted EPS $1.27-$1.31, consensus $1.29
Subscribe for More Information
16:28 EDTESRXExpress Scripts narrows FY14 EPS view to $4.84-$4.92 from $4.82-$4.94
Consensus $4.86.
16:27 EDTESRXExpress Scripts reports Q2 adjusted EPS $1.23, consensus $1.22
Reports Q2 revenue $25.11B, consensus $24.38B.
15:53 EDTESRXNotable companies reporting after market close
Subscribe for More Information
07:55 EDTESRX, CTRXLeerink a buyer of Catamaran ahead of Q2 results
Leerink says it's a buyer of Catamaran (CTRX) ahead of the company's Q2 results as it believes shares have more room to run. The firm is cautious on Express Scripts (ESRX) after hearing from a specialist that service challenges may impact the company's 2015 and 2016 selling seasons. The firm remains positive on CVS Caremark (CVS), but notes shares have outperformed and the company could see retail pressure from recent drug inflation trends.
July 28, 2014
12:21 EDTESRXOn The Fly: Midday Wrap
Subscribe for More Information
10:26 EDTESRXExpress Scripts August weekly volatility elevated into Q2 and outlook
Subscribe for More Information
06:22 EDTESRXHorizon Pharma said Duexis, Vimovo to be placed on CVS, Express exlclusion lists
Subscribe for More Information
July 23, 2014
09:30 EDTESRXExpress Scripts downgraded to Neutral from Buy at Cleveland Research
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use